

Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Versior 2.0	n Revision Date: 09.04.2021		S Number: 44873-00004	Date of last issue: 10.10.2020 Date of first issue: 30.09.2019	
1. PRC	DUCT AND COMPANY ID	ENT	IFICATION		
Pr	oduct name	:	Olmesartan / Am Formulation	llodipine Besylate (3.5%) / Hydrochlorothiazide	
Ma	anufacturer or supplier's o	deta	ils		
Co	ompany	:	Organon & Co.		
Ac	ddress	:	30 Hudson Stree Jersey City, New	et, 33nd floor v Jersey, U.S.A 07302	
Te	elephone	:	551-430-6000		
Er	Emergency telephone number		215-631-6999		
E-	mail address	:	EHSSTEWARD@organon.com		
Re	ecommended use of the c	hem	ical and restriction	ons on use	
Re	ecommended use	:	Pharmaceutical		

2. HAZARDS IDENTIFICATION

GHS Classification Serious eye damage/eye irri- tation	:	Category 2
Reproductive toxicity	:	Category 1A
Specific target organ toxicity - repeated exposure	:	Category 2 (Kidney, Parathyroid gland)
GHS label elements		
Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H319 Causes serious eye irritation. H360D May damage the unborn child. H373 May cause damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.
Precautionary statements	:	Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust.



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0	Revision Date: 09.04.2021	SDS Number: 4944873-00004	Date of last issue: 10.10.2020 Date of first issue: 30.09.2019			
			n thoroughly after handling. tective gloves/ protective clothing/ eye protec- ction.			
		for several minu easy to do. Con P308 + P313 IF attention.	P338 IF IN EYES: Rinse cautiously with water utes. Remove contact lenses, if present and ntinue rinsing. Fexposed or concerned: Get medical advice/ eye irritation persists: Get medical advice/ at-			
		Storage: P405 Store lock	ked up.			
		Disposal:				
		P501 Dispose o disposal plant.	of contents/ container to an approved waste			

Other hazards which do not result in classification

May form explosible dust-air mixture if dispersed.

Contact with dust can cause mechanical irritation or drying of the skin.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	:	Mixture
	-	1111/1010

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 30 -< 50
Starch	9005-25-8	>= 30 -< 50
Olmesartan	144689-63-4	>= 10 -< 20
Hydrochlorothiazide	58-93-5	>= 1 -< 10
Amlodipine Besylate	652969-01-2	>= 2.5 -< 10

4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.



Version 2.0	Revision Date: 09.04.2021		OS Number: 44873-00004	Date of last issue: 10.10.2020 Date of first issue: 30.09.2019			
	mportant symptoms fects, both acute and	:	Get medical atter If swallowed, DO Get medical atter Rinse mouth thor Causes serious e May damage the May cause dama exposure. Contact with dust	NOT induce vomiting. ntion. oughly with water. eye irritation.			
	tion of first-aiders	:	and use the record when the potentia	ers should pay attention to self-protection, mmended personal protective equipment al for exposure exists (see section 8).			
Notes	to physician	•	Treat symptomat	ically and supportively.			
5. FIREFIG	HTING MEASURES						
Suitab	le extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (0 Dry chemical				
Unsuit media	able extinguishing	:	High volume water jet				
	ic hazards during fire- g	:	concentrations, a potential dust exp Do not use a solid fire.	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a plosion hazard. d water stream as it may scatter and spread bustion products may be a hazard to health.			
Hazardous combustion prod- ucts		:	Carbon oxides Nitrogen oxides (NOx) Chlorine compounds Sulphur oxides				
ods	Specific extinguishing meth- ods		Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.				
	al protective equipment fighters	:		e, wear self-contained breathing apparatus. tective equipment.			

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Versi 2.0	ion	Revision Date: 09.04.2021		9S Number: 44873-00004	Date of last issue: 10.10.2020 Date of first issue: 30.09.2019
				Local authorities s cannot be contain	should be advised if significant spillages ed.
		ls and materials for ment and cleaning up	:	tainer for disposal Avoid dispersal of with compressed Dust deposits sho es, as these may leased into the atr Local or national r posal of this mate employed in the c mine which regula Sections 13 and 1	dust in the air (i.e., clearing dust surfaces
7. HA	ANDLIN	IG AND STORAGE			
-	Technic	cal measures	:	causing an explos	precautions, such as electrical grounding
I	Local/T	otal ventilation	:		tion is unavailable, use with local exhaust
	Advice	on safe handling	:	Do not get on skir Do not breathe du Do not swallow. Do not get in eyes Wash skin thoroug Handle in accorda practice, based or sessment Keep container tig Minimize dust ger Keep container clu Keep away from h Do not eat, drink o	ist. ghly after handling. ance with good industrial hygiene and safety in the results of the workplace exposure as-
	Conditio	ons for safe storage	:	Keep in properly I Store locked up. Keep tightly close	abelled containers. d. ce with the particular national regulations.
I	Materia	lls to avoid	:		the following product types:

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

	Components	CAS-No.	Value type	Control parame-	Basis
--	------------	---------	------------	-----------------	-------



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

ersion)	Revision Date: 09.04.2021	SDS Number: 4944873-00004		st issue: 10.10.2020 rst issue: 30.09.2019		
			(Form of exposure)	ters / Permissible concentration		
Cellu	ose	9004-34-6	PEL (long term)	10 mg/m3	SG OEL	
			TWA	10 mg/m3	ACGIH	
Starc	h	9005-25-8	PEL (long term)	10 mg/m3	SG OEL	
			TWA	10 mg/m3	ACGIH	
Olme	sartan	144689-63-4	TWA	30 µg/m3 (OEB 3)	Internal	
			Wipe limit	300 µg/100 cm ²	Internal	
Hydro	ochlorothiazide	58-93-5	TWA	100 µg/m3 (OEB 2)	Internal	
Amlo	dipine Besylate	652969-01-2	TWA	20 µg/m3 (OEB 3)	Internal	
			Wipe limit	100 µg/100 cm ²	Internal	
	onal protective equip	nent		nd the environment.		
	onal protective equip	nent		ntilation is not available	e or expo-	
Fil	ter type		uidelines, use r	tes exposures outside espiratory protection.	the rec-	
Hand	protection aterial	: Chemical-res				
Eye p	protection	 Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. Work uniform or laboratory coat. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. 				
	and body protection ene measures					

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	tablet
Colour	:	No data available



Version Revision Date: 2.0 09.04.2021	SDS Number:Date of last issue: 10.10.20204944873-00004Date of first issue: 30.09.2019
Odour	: No data available
Odour Threshold	: No data available
рН	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	g : No data available
Flash point	: No data available
Evaporation rate	: Not applicable
Flammability (solid, gas)	: No data available
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: Not applicable
Relative vapour density	: Not applicable
Relative density	: No data available
Density	: No data available
Solubility(ies) Water solubility	: No data available
Partition coefficient: n- octanol/water	: Not applicable
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity Viscosity, kinematic	: Not applicable
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle size	: No data available



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944873-00004	Date of first issue: 30.09.2019

10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. Dust can form an explosive mixture in air. Can react with strong oxidizing agents.				
Conditions to avoid Incompatible materials Hazardous decomposition products		Avoid dust formation. Oxidizing agents No hazardous decomposition products are known.				

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg
		Method: Calculation method

Components:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg
Starch:		
Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg
Olmesartan:		
Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg
		LD50 (Mouse): > 2,000 mg/kg
		LD50 (Dog): > 1,500 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available



Versio 2.0	on	Revision Date: 09.04.2021		S Number: 44873-00004	Date of last issue: 10.10.2020 Date of first issue: 30.09.2019
11					
	Hydroc	hlorothiazide:			
	•	ral toxicity	:	LD50 (Rat): > 2,75	50 mg/kg
				LD50 (Mouse): > 2	2,830 mg/kg
		oxicity (other routes of stration)	:	LD50 (Rat): 990 m Application Route	
				LD50 (Mouse): 59 Application Route	
		pine Besylate:			
Þ	Acute o	ral toxicity	:	LD50 (Rat): 393 m	ng/kg
-		orrosion/irritation ssified based on availa	ble	information.	
<u>c</u>	Compo	onents:			
C	Olmesa	artan:			
F	Remark	S	:	No data available	
F	Hydroc	hlorothiazide:			
	Species		:	Rabbit	
F	Result		:	No skin irritation	
		s eye damage/eye irri serious eye irritation.	tati	on	
<u>c</u>	Compo	onents:			
5	Starch:	:			
	Species Result	3	:	Rabbit No eye irritation	
C	Olmesa	artan:			
	Species	6	:	Rabbit	
F	Result Method		:	Moderate eye irrita Draize Test	ation
F	Hydroc	hlorothiazide:			
	Species		:	Rabbit	
	Result		:	Mild eye irritation	
Å	Amlodi	pine Besylate:			
	Species Result	3	:	Rabbit Severe irritation	
II	งธอนแ		•		



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944873-00004	Date of first issue: 30.09.2019

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Starch:

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Test Type Exposure routes Species Result	:	negative

Olmesartan:

Exposure routes Remarks	:	Skin contact
Remarks	:	No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Cellulose:

Genotoxicity in vitro :	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo :	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative
Starch:	
Starch: Genotoxicity in vitro :	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Olmosartan:	
Genotoxicity in vitro :	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Mutagenicity (in vitro mammalian cytogenetic test) Result: negative
II	Test Type: Chromosome aberration test in vitro



Version 2.0	Revision Date: 09.04.2021	SDS Number:Date of last issue: 10.10.20204944873-00004Date of first issue: 30.09.2019
		Test system: Chinese hamster lung cells Result: positive
		Test Type: Mouse Lymphoma Result: negative
Genc	otoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: negative
	n cell mutagenicity - ssment	: Weight of evidence does not support classification as a germ cell mutagen.
Hydr	ochlorothiazide:	
	otoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative
		Test Type: sister chromatid exchange assay Test system: Chinese hamster ovary cells Result: positive
		Test Type: in vitro assay Test system: mouse lymphoma cells Result: positive
Geno	otoxicity in vivo	: Test Type: Chromosomal aberration Species: Chinese hamster Cell type: Bone marrow Result: negative
		Test Type: in vivo assay Species: Mouse Cell type: Bone marrow Result: negative
Germ Asse	n cell mutagenicity - ssment	: Weight of evidence does not support classification as a germ cell mutagen.
Amic	odipine Besylate:	
	otoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosome aberration test in vitro Result: negative



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

ersion)	Revision Date: 09.04.2021		Number: 1873-00004	Date of last issue: 10.10.2020 Date of first issue: 30.09.2019
Carci	nogenicity			
Not cl	assified based on av	ailable in	formation.	
<u>Com</u>	oonents:			
Cellu	lose:			
Speci	es	: F	Rat	
	cation Route	: 1	ngestion	
	sure time		2 weeks	
Resu	t	: r	negative	
Olme	sartan:			
Speci	es	: F	Rat	
Applic	cation Route		Dral	
	sure time		2 Years	
Resu	lt	: r	negative	
Speci	es	: 1	Nouse	
	cation Route	: (Dral	
Expos	sure time	: 6	6 Months	
Resu	lt	: r	negative	
Hydro	ochlorothiazide:			
Speci	es	: 1	Nouse, female	
	cation Route		Dral	
	sure time		2 Years	
Resu	lt	: r	negative	
Speci		: 1	<i>l</i> louse, male	
Applic	cation Route	: (Dral	
	sure time		2 Years	
Resu	t	: 6	equivocal	
Speci	es		Rat, male and fo	emale
Applic	cation Route		Dral	
	sure time		2 Years	
Resu	I	: r	negative	
	dipine Besylate:			
Speci			Nouse	
	cation Route		Dral	
	sure time		2 Years	
Resu	IT	: r	negative	
Speci			Rat	
	cation Route		Dral	
Expos	sure time		2 Years	
Resu	IL	: r	negative	

May damage the unborn child.



Version 2.0	Revision Date: 09.04.2021	SDS Number:Date of last issue: 10.10.20204944873-00004Date of first issue: 30.09.2019
Com	ponents:	
Cellu	lose:	
Effect	ts on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effec ment	ts on foetal develop-	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative
Olme	esartan:	
Effec	ts on fertility	: Test Type: Fertility Species: Rat Application Route: Oral Fertility: NOAEL: 1,000 mg/kg body weight Result: No effects on fertility
Effect ment	ts on foetal develop-	: Test Type: Development Species: Rat Application Route: Oral Dose: 1000 milligram per kilogram Result: No teratogenic effects
		Test Type: Development Species: Rabbit Application Route: Oral Dose: 1 milligram per kilogram Result: No teratogenic effects
		Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: >= 1.6 mg/kg body weight Symptoms: Malformations were observed., Reduced body weight Result: Effects on postnatal development
Repro	oductive toxicity - As- nent	: Positive evidence of adverse effects on development from human epidemiological studies.
Hydr	ochlorothiazide:	
	ts on fertility	: Test Type: Fertility Species: Rat, male and female Application Route: oral (feed) Fertility: NOAEL: 4 mg/kg body weight Result: Effects on fertility
		Test Type: Fertility Species: Mouse, male and female



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0	Revision Date: 09.04.2021	SDS Number: 4944873-00004	Date of last issue: 10.10.2020 Date of first issue: 30.09.2019
		Application Ro Fertility: NOAE Result: Effects	L: 100 mg/kg body weight
Effect ment	s on foetal develop-		e
Amlo	dipine Besylate:		
	s on fertility	Species: Rat Application Ro	L: 10 mg/kg body weight
		Species: Rabb Application Ro	ute: Ingestion L: 25 mg/kg body weight
Effect ment	s on foetal develop-	Species: Rat Application Ro Developmenta	bryo-foetal development ute: Ingestion I Toxicity: LOAEL: 10 mg/kg body weight on foetal development
		Species: Rabb Application Ro Developmenta	
		Species: Mous Application Ro Developmenta Result: Effects	

STOT - single exposure

Not classified based on available information.



Version 2.0	Revision Date: 09.04.2021		OS Number: 44873-00004	Date of last issue: 10.10.2020 Date of first issue: 30.09.2019
	- repeated exposure cause damage to organs	s (Ki	dney, Parathyroid (gland) through prolonged or repeated expo-
Com	ponents:			
Hydro	ochlorothiazide:			
Targe	et Organs ssment	:	Kidney, Parathyrc Causes damage t exposure.	o organs through prolonged or repeated
Repe	ated dose toxicity			
<u>Com</u>	ponents:			
Cellu	lose:			
		:	Rat >= 9,000 mg/kg Ingestion 90 Days	
Starc	h:			
	EL cation Route sure time	:	Rat >= 2,000 mg/kg Skin contact 28 Days OECD Test Guide	eline 410
Olme	sartan:			
Speci NOAI Applio	ies EL cation Route sure time	:	Rat 2,000 mg/kg Oral 24 Months No significant adv	rerse effects were reported
Hydro	ochlorothiazide:			
Speci LOAE Applic Expos	ies	:	Rat, male and fen 10 mg/kg Oral 2 yr Kidney, Parathyrc	
	EL cation Route sure time	: : : : : : : : : : : : : : : : : : : :	Mouse, male and 300 - 550 mg/kg Oral 2 yr No significant adv	female rerse effects were reported
Speci Applie	ies cation Route	:	Dog 50 - 200 mg/kg Oral	



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0	Revision Date: 09.04.2021		DS Number: 944873-00004	Date of last issue: 10.10.2020 Date of first issue: 30.09.2019			
Expos Targe	Exposure time Target Organs		9 Months Parathyroid gland				
Speci NOAE Applio	EL cation Route sure time	:	Rat 15 mg/kg Oral 90 d No significant adv	verse effects were reported			
Not cl Comp Hydro	ration toxicity assified based on avail ponents: pochlorothiazide: piration toxicity classifie						
-	rience with human ex ponents:	posi	ure				
	sartan:						
	ontact	:	Symptoms: Eye in Symptoms: hypot Remarks: May ca Based on Human	ension use harm to the unborn child.			
Hydro	ochlorothiazide:						
Eye c Inges	ontact tion	:		rritation ness, Headache, Fatigue, Nausea, Ab- potension, dry mouth, electrolyte imbalance,			
Amlo	dipine Besylate:						
Eye c Inges	ontact tion	:	Symptoms: Seve Symptoms: Naus Oedema, Palpitat	ea, Abdominal pain, Fatigue, Headache,			
12. ECOL	OGICAL INFORMATIO	N					
Ecoto	oxicity						
Com	oonents:						
Cellu							
	ity to fish	:	Exposure time: 4	ipes (Japanese medaka)): > 100 mg/l 8 h on data from similar materials			

Hydrochlorothiazide:

- Toxicity to fish
- : LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version 2.0	Revision Date: 09.04.2021		DS Number: 44873-00004	Date of last issue: 10.10.2020 Date of first issue: 30.09.2019
II			Exposure time: 96	6 h
	icity to daphnia and other atic invertebrates	:	EC50 (Daphnia m Exposure time: 48	nagna (Water flea)): > 500 mg/l 3 h
Am	lodipine Besylate:			
	icity to fish	:	LC50 (Pimephale Exposure time: 96	s promelas (fathead minnow)): 2.7 mg/l 6 h
	icity to daphnia and other atic invertebrates	:	EC50 (Daphnia m Exposure time: 48	nagna (Water flea)): 3.2 mg/l 3 h
Tox plar	icity to algae/aquatic nts	:	IC50 (Pseudokirc Exposure time: 72 Method: OECD T	
Per	sistence and degradabil	ity		
<u>Cor</u>	nponents:			
Cel	lulose:			
Biod	degradability	:	Result: Readily bi	odegradable.
Нус	Irochlorothiazide:			
Stal	pility in water	:	Hydrolysis: 46.2 9	%(96 h)
Bio	accumulative potential			
<u>Cor</u>	nponents:			
Par	Iodipine Besylate: tition coefficient: n- anol/water	:	log Pow: 3	
Mol	bility in soil data available			
	er adverse effects data available			
	POSAL CONSIDERATION	IS		
147				

Waste from residues Contaminated packaging		Dispose of in accordance with local regulations. Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.
---	--	--

14. TRANSPORT INFORMATION

International Regulations



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.20
2.0	09.04.2021	4944873-00004	Date of first issue: 30.09.20

020 019

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and Environmental Protection and Management (Hazard- ous Substances) Regulations	:	Not applicable
Fire Safety (Petroleum and Flammable Materials) Regulations	:	Not applicable

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

16. OTHER INFORMATION

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format	:	dd.mm.yyyy		
Full text of other abbreviations				
ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)		
SG OEL	:	Singapore. Workplace Safety and Health Act - First Schedule		
		Permissible Exposure Limits of Toxic Substances		



Olmesartan / Amlodipine Besylate (3.5%) / Hydrochlorothiazide Formulation

2

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
2.0	09.04.2021	4944873-00004	Date of first issue: 30.09.2019

ACGIH / TWA SG OEL / PEL (long term) 8-hour, time-weighted average Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN